 The primary objective is to demonstrate improved A1c in study subjects with type 1 and type 2 diabetes using the OneTouch Verio Flex BGM and the OneTouch Reveal Mobile APP system over a period of 24 weeks, compared to subjects using the OneTouch Verio Flex BGM. 